Shrink Nanotechnologies, a leading nanotechnology firm that develops various products and licensing opportunities in fields such as solar power manufacture, clinical diagnostics and sensing, biotechnology research and marketing of innovative tools, proclaimed that the company has signed a licensing contract with Corning Incorporated.
As per the agreement Shrink upholds an absolute authority to exploit and sublicense the innovative patent-pending microfluidic system of Corning for nearly eight years.
Corning’s patent-awaiting microfluidic technology has been publicized in a Lab on a Chip academic journal and has attained remarkable response from the academic and commercial sectors. This modular technology employs a unique plug and play microfluidics system for use in integral PSI connectors, pumps and electronics and can be widely exploited for varied commercial research purposes requiring high-speed microfluidic prototyping configuration. This unique property is used in biomedical, biochemical, cell-oriented drug discovery and many other applications.
According to Mark L. Baum, CEO at Shrink Nanotechnologies, the company focuses on developing cost-effective, standard, sensitive microfluidic devices to meet the demand of the progressive microfluidics market and that the company is pleased to release highly-economical NanoShrink devices based on the research on Corning’s microfluidic systems for carrying out significant biotechnological researches. Baum added that Shrink Nanotechnologies is pleased to work with Corning or marketing this valuable technology world-wide.